Valneva : A Q2 and Q3 which are set to be trickier
>Impact of COVID-19 still limited… - This morning Valneva reported its Q1 2020 results. The impact of COVID-19 is still marginal but is expected to accelerate significantly in the second and third quarters of 2020. Management anticipates a gradual return to normal as of Q4. The top line rose +1% y-o-y, i.e. +4% above expectations at € 33.9m. The positive surprise concerns EBITDA, which came out positive at € 2.4m, due in particular to a good performance in terms of th...Valneva, together with its subsidiaries, is focused on vaccine development and antibody discovery. Co. generates revenue from both its marketed product, a vaccine for the prevention of Japanese encephalitis (IXIARO®/JESPECT®), commercial partnerships around a portfolio of product candidates and licensed technology platforms (EB66® cell line, VIVA,Screen antibody discovery technology, and the IC31® adjuvant) developed by Co. Related business activities include product research and development, regulatory and clinical activities, manufacturing of commercial product and advanced clinical product candidates, as well as administrative, corporate development, and marketing and sales activities.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.